Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.The stock has underperformed the sector and the S&P 500 Index during...
Cytokinetics, Incorporated CYTK announced that the late-stage COMET-HF study on pipeline candidate, omecamtiv mecarbil, has started.COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart...
Cytokinetics, Incorporated CYTK announced that the FDA has accepted the company’s new drug application (NDA) for lead pipeline candidate, aficamten.Aficamten is a next-in-class cardiac myosin inhibitor....
ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.
The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY announcing their results. AbbVie’s ABBV schizophrenia candidate, added from a recent...
Bayer AG BAYRY reported third-quarter 2024 core earnings of 7 cents per American Depositary Receipt (ADR), which missed the Zacks Consensus Estimate of 17 cents. The company reported earnings of 10 cents...
Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected third-quarter results despite lower sales from its lead drug, Eylea. Revenues climbed 11% to $3.72 billion, driven by growth in Eylea...
Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali (ribociclib)...
Bayer BAYRY announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (“EMA”) for its pipeline candidate elinzanetant.The MAA is seeking approval...
Roche RHHBY announced that the FDA has approved pipeline candidate, inavolisib, for the treatment of breast cancer, under the brand name Itovebi.The drug is approved in combination with Pfizer’s Ibrance...